开源证券给予佐力药业买入评级，2025H1利润快速增长，战略性拓展布局大健康

Group 1 - The core viewpoint of the report is that Zhaoli Pharmaceutical (300181.SZ, latest price: 19.9 yuan) is given a "buy" rating due to its stable revenue growth from its Wuling and Bailing product series, with most products showing steady improvement in gross margins [2] - The company is focusing on innovation in its advantageous fields, leveraging technology to drive growth [2] Group 2 - The report highlights the potential risks, including policy fluctuations, underperformance in product sales, and slower-than-expected progress in new product development [2]